These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1848 related articles for article (PubMed ID: 8436442)

  • 1. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine.
    Shrayer D; Kouttab N; Maizel A; Wanebo H; Hearing VJ; Gersten DM
    Int J Cancer; 1993 Feb; 53(4):696-702. PubMed ID: 8436442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of interleukin-2, natural killer cell activity and anti-melanoma antibodies resulting from immunization of mice with formalinized extracellular antigens (FECA) of murine melanoma.
    Shrayer D; Koness J; Maizel A; Wanebo H
    Melanoma Res; 1992 May; 2(1):47-56. PubMed ID: 1643424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological characterization of a shared melanoma-associated antigen of mouse melanomas: relationship to the B700 glycoprotein.
    DeLeo AB; Hearing VJ; Vieira WD; Law LW
    Melanoma Res; 1991; 1(2):133-40. PubMed ID: 1668533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma.
    Shrayer D; Bogaars H; Gersten D; Hearing V; Maizel A; Wanebo H
    J Surg Oncol; 1994 Sep; 57(1):50-6. PubMed ID: 8065154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of immunogenic B16 melanoma-associated antigens.
    Johnston D; Schachne JP; Bystryn JC
    J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
    Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
    Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intracellular association of B700 and B50 murine melanoma antigens and their role in tumor rejection.
    Gersten DM; Williams LJ; Moody D; Montague PM; Law LW; Hearing VJ
    Int J Cancer; 1989 Mar; 43(3):497-500. PubMed ID: 2925280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B700 antigen as a component of an antimelanoma vaccine: formalinized extracellular antigens.
    Shrayer D; Gersten DM; Koness J; Maizel A; Wanebo H; Hearing VJ
    Pigment Cell Res; 1992 Sep; 5(3):107-12. PubMed ID: 1409447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model.
    Shrayer D; Koness J; Kouttab N; Bogaars H; Hearing VJ; Gersten DM; Maizel A; Wanebo H
    J Surg Oncol; 1993 Mar; 52(3):142-9. PubMed ID: 8441268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine melanoma-specific tumor rejection activity elicited by a purified, melanoma-associated antigen.
    Hearing VJ; Gersten DM; Montague PM; Vieira WD; Galetto G; Law LW
    J Immunol; 1986 Jul; 137(1):379-84. PubMed ID: 3711669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine.
    Baral R; Mandal I; Chattopadhyay U
    Int Immunopharmacol; 2005 Jul; 5(7-8):1343-52. PubMed ID: 15914339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of monoclonal antibodies against the B700 murine melanoma antigen and their antimetastatic properties.
    Gersten DM; Moody D; Vieira WD; Law LW; Hearing VJ
    Biochim Biophys Acta; 1992 Feb; 1138(2):109-14. PubMed ID: 1540656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity between murine melanoma antigen B700 and a human melanoma-associated antigen (M-66) recognized by autologous antibody: evidence suggesting shared epitopes.
    Toporowicz A; Gersten DM; Hearing VJ; Brown WE; Vlock DR
    Biochim Biophys Acta; 1993 Aug; 1182(1):51-6. PubMed ID: 7688577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of B700 cross-reactive antigens on human and other animal melanomas.
    Gersten DM; Hearing VJ
    Pigment Cell Res; 1988; 1(6):434-8. PubMed ID: 3237611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
    Ravindranath MH; Brazeau SM; Morton DL
    Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of melanoma cell surface antigens immunogenic in mice.
    Johnston D; el Rouby S; Bystryn JC
    Cancer Biother; 1994; 9(1):29-38. PubMed ID: 7812355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine.
    Johnston D; Bystryn JC
    J Natl Cancer Inst; 1991 Sep; 83(17):1240-5. PubMed ID: 1870150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.